Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

CG Oncology (CGON) Net Income towards Common Stockholders (2023 - 2025)

CG Oncology filings provide 3 years of Net Income towards Common Stockholders readings, the most recent being -$41.3 million for Q4 2025.

  • On a quarterly basis, Net Income towards Common Stockholders fell 29.74% to -$41.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$160.8 million, a 82.7% decrease, with the full-year FY2025 number at -$161.0 million, down 82.87% from a year prior.
  • Net Income towards Common Stockholders hit -$41.3 million in Q4 2025 for CG Oncology, up from -$43.7 million in the prior quarter.
  • In the past five years, Net Income towards Common Stockholders ranged from a high of -$12.4 million in Q1 2023 to a low of -$43.7 million in Q3 2025.
  • Median Net Income towards Common Stockholders over the past 3 years was -$21.4 million (2023), compared with a mean of -$26.4 million.
  • Biggest five-year swings in Net Income towards Common Stockholders: decreased 16.51% in 2024 and later tumbled 119.14% in 2025.
  • CG Oncology's Net Income towards Common Stockholders stood at -$22.5 million in 2023, then crashed by 41.39% to -$31.8 million in 2024, then dropped by 29.74% to -$41.3 million in 2025.
  • The last three reported values for Net Income towards Common Stockholders were -$41.3 million (Q4 2025), -$43.7 million (Q3 2025), and -$41.4 million (Q2 2025) per Business Quant data.